Nexletol — the bempedoic acid tablets, an ATP-citrate lyase (ACL) inhibitor upstream of HMG-CoA reductase in the cholesterol biosynthesis pathway, providing oral LDL-C reduction without the myopathic adverse effects associated with statin therapy — creating the most clinically differentiated segment in dyslipidemia pharmacotherapy, with the Nexletol Market reflecting bempedoic acid...